Pratap C. Naha
About Pratap C. Naha
Pratap C. Naha is an Associate Director at Ocugen, where he has worked since 2019. He has extensive experience in pharmacology, toxicology, and nanomedicine, having held various research positions in both academic and industry settings.
Work at Ocugen
Pratap C. Naha serves as Associate Director at Ocugen, a position he has held since 2019. His role involves expertise in gene therapy and nanotechnology, which are integral to the company's focus on innovative treatments. Naha's responsibilities include overseeing projects related to drug delivery systems, contributing to the development of therapies aimed at addressing unmet medical needs. Ocugen is located at 263 Great Valley Pkwy, Malvern, PA 19355.
Education and Expertise
Pratap C. Naha earned a PhD in Pharmacology and Toxicology from Technological University Dublin, completing his studies from 2008 to 2011. He also holds an M.Pharmacy in Pharmacology from Annamalai University, which he completed between 2004 and 2006, and a B. Pharmacy from Biju Patnaik University of Technology, obtained from 2000 to 2006. His educational background supports his expertise in gene therapy and nanotechnology.
Background
Naha has a diverse professional background in pharmacology and toxicology. He worked as a Postdoctoral Fellow at the University of Pennsylvania from 2012 to 2017, focusing on nanomedicine. Prior to that, he was a Postdoctoral Researcher at the Dublin Institute of Technology from 2008 to 2012. His earlier experience includes a role as a Research Associate at the University of Pennsylvania School of Medicine from 2017 to 2019 and as a Research Assistant at the National Institute of Immunology in New Delhi from 2006 to 2008.
Research Experience
Throughout his career, Pratap C. Naha has engaged in significant research in the fields of pharmacology and toxicology. His work at the University of Pennsylvania involved nanomedicine, while his time at the Dublin Institute of Technology focused on similar themes. His research experience has contributed to advancements in drug delivery systems, a key area of focus in his current position at Ocugen.